ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Lumasiran (Primary)
- Indications Primary hyperoxaluria
- Focus Registrational; Therapeutic Use
- Acronyms ILLUMINATE-A
- Sponsors Alnylam Pharmaceuticals
- 09 Nov 2019 According to an Alnylam media release, results are expected later this year
- 17 Jun 2019 According to an Alnylam media release, enrollment has been completed for this study.
- 17 Jun 2019 Status changed from recruiting to active, no longer recruiting.